IL-2 activated cell-mediated immunotherapy: Control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2

S. Slavin, A. Ackerstein, E. Kedar, L. Weiss

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

The present experiments were designed to investigate whether it might be possible to combine ther therapeutic benefits of autologous BMT and allogeneic BMT following administration of T-lymphocyte deplete marrow allografts with additional immunotherapy following BMT. The tumor model used for investigating graft vs leukemia (GVL) effects was the muring B-cell leukemia (BCL1), a spontaneous, nonimmunogenic, highly lethal leukemia of BALB/c origin. Immunotherapy with high dose recombinant human interleukin-2 (IL2) (105 Cetus units x 3/day intraperitoneally (IP) for 5 days) produced significant anti-tumor effects in BCL1-bearing mice. BALB/c mice inoculated with 103 BCL1 leukemia cells received were treated on day -1 with cyclophosphamide 100 mg/kg and transplanted with normal syngeneic BM cells on day 0. Highdose IL2 (100,000 Cetus Units x 3/day IP x 5 consecutive days) was initiated on day +1, +7, or +21 following BMT. Optimal time for administration of IL2 was noted at 3 weeks post-BMT with 90% of the mice surviving with no evidence of disease >1 year. An experimental model designed to study GVL effects in a state of minimal residual disease following T-cell depleted allogeneic BMT indicated that mice receiving low dose of BCL1 challenge (104) were successfully treated by either IL2 (2x104 Cetus units x 2/day IP x 3 days), allogeneic spleen cells (106 on day +1, 107 on day +5 and 5x107 on day +9) alone and certainly following a combination of both. Mice inoculated with 105 BCL1 cells following BMT developed leukemia after IL2 treatment alone, but remained disease-free following administration of allogneneic spleen cells or both allogeneic spleen cells and IL2. In contrast, mice inoculatd with a high dose of BCL1 (106) showed no longterm antileukemia effects following combination of IL2 and allogeneic spleen cells. Our data suggests that allogeneic immunocompetent lymphocytes may be used as a therapeutic tool against leukemic relapse even following initial reconstitution with T cell depleted bone marrow allograft in minimal residual disease state and that these GVL effects mediated by allogeneic lymphocytes may be augmented by IL2. A similar approach may prove beneficial in conjunction with autologous and allogeneic BMT in man as long as GVHD may be prevented or controlled.

Original languageEnglish
Pages (from-to)86-89
Number of pages4
JournalBone Marrow Transplantation
Volume6
Issue numberSUPPL. 1
StatePublished - 1990
Externally publishedYes

Fingerprint

Dive into the research topics of 'IL-2 activated cell-mediated immunotherapy: Control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2'. Together they form a unique fingerprint.

Cite this